Harmony Biosciences Holdings, Inc. (HRMY)

Several events have impacted HRMY's stock price in the past six months. The company reported Q2 2025 earnings with an EPS of $0.68, missing estimates, leading to a downgrade. They pre-announced strong preliminary Q3 2025 results and increased revenue guidance. However, the Phase 3 study of ZYN002 in Fragile X Syndrome did not meet its primary endpoint, causing the stock to fall. As of October 17, 2025, the stock price was $25.90 per share, representing a decline from October 21, 2024. The stock has experienced a rise over the last month but a decrease over the last year.

There is no explicit information available in the provided search results indicating demand seasonality for Harmony Biosciences Holdings, Inc.'s products and services.

Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for rare neurological diseases and other neurological conditions with unmet medical needs. Their flagship product is WAKIX (pitolisant), a first-in-class molecule that enhances histamine signaling in the brain and is approved for the treatment of excessive daytime sleepiness (EDS) and cataplexy in adult patients with narcolepsy. The company's pipeline includes HBS-102, an investigational melanin-concentrating hormone receptor 1 (MCHR1) antagonist, ZYN002, a pharmaceutically manufactured synthetic cannabidiol, EPX-100 (clemizole hydrochloride) for Dravet syndrome and Lennox-Gastaut syndrome, and EPX-200 (a liquid formulation of lorcaserin) for developmental and epileptic encephalopathies (DEE).

Harmony Biosciences Holdings, Inc. focuses on developing and commercializing its therapies primarily in the United States and is headquartered in Plymouth Meeting, Pennsylvania.

Harmony Biosciences has maintained a "Moderate Buy" consensus rating from analysts, with an average rating score of 2.90. The company has a neutral news sentiment score. While there have been positive developments, the disappointing Phase 3 trial results for ZYN002 in Fragile X Syndrome negatively impacted investor sentiment and the stock price.

Harmony Biosciences Holdings, Inc. is predominantly owned by institutional shareholders, who hold approximately 89.07% of the company's stock. Insiders own about 25.79%, while retail investors hold 0.00%. Major institutional owners include BlackRock, Inc., Valor Management LLC, The Vanguard Group, Inc., Fmr LLC, and State Street Corp. Marshman Fund Trust II is the largest individual shareholder.